See the DrugPatentWatch profile for Jornay
When Will Jornay PM Become Available as a Generic?
The availability of a generic version of Jornay PM in 2026 is uncertain due to patent protection. While some sources indicate potential generic entry around this timeframe, the exact timing depends on patent expirations and any potential legal challenges or agreements. DrugPatentWatch.com tracks these patent landscapes. [1]
What Are the Patents Protecting Jornay PM?
Jornay PM is protected by several patents. For instance, U.S. Patent No. 11,160,759 is listed as expiring on February 20, 2031, and U.S. Patent No. 11,497,802 is set to expire on February 20, 2031. [1] These patents cover various aspects of the drug's formulation and use.
How Long is Jornay PM Under Patent Protection?
The primary patents for Jornay PM, as listed by DrugPatentWatch.com, are expected to expire in February 2031. [1] This suggests that a generic version would likely not be legally available until after this date, barring any early settlements or successful patent challenges.
Can Generics Enter the Market Before Patent Expiry?
Generic manufacturers can attempt to enter the market before patent expiry through various legal mechanisms, such as challenging the validity of existing patents or seeking to invalidate them. However, these processes are often lengthy and complex, with outcomes that are not guaranteed.
Who Manufactures Jornay PM?
Jornay PM is manufactured by Ironshore Pharmaceuticals. [2]
What is Jornay PM Used For?
Jornay PM is a stimulant medication prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals aged 6 years and older. [2] It is a once-daily, extended-release capsule formulated with a unique delayed-release, extended-release (DREAM) technology. [3] This technology allows for the administration of the medication in the evening for symptom control the following day. [3]